9 Analysts Have This To Say About Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has received varied analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased to $77.67. The company has shown significant revenue growth but faces challenges with ROE and ROA.
October 16, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech has received predominantly bullish analyst ratings, with an increased average price target of $77.67. The company has shown strong revenue growth but faces challenges with ROE and ROA.
The majority of analysts have given bullish ratings, indicating positive sentiment. The increase in the average price target suggests expectations of future growth. The company's strong revenue growth supports this outlook, although challenges with ROE and ROA may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100